

Clatterbridge Cancer Centre (CCC) Performance in Delivering Research (PID) Q2 2016/17

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients (Planned study end date)	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
15/LO/0016	MONARCH-3 - A randomized, double-blind, placebo-controlled, phase 3 study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-nega	Number Agreed	6	Date Agreed	30/11/2015	0	23/10/2015	Recruitment Finished	Short recruitment window, study only open to recruitment for 5 months. 1 patient consented but ineligible on screening investigations.
13/SC/0478	COLUMBUS: NCRN 567 - A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma	Number Agreed	3	Date Agreed	21/08/2017	1	18/11/2015	Recruitment Finished	Study closed before target recruitment achieved.
14/NW/1258	ARAMIS: NCRN - 3041:ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	Number Agreed	6	Date Agreed	30/06/2020	6	21/12/2015	Recruitment Finished	Target Achieved
14/SC/1014	JANUS 1: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line	Number Agreed	5	Date Agreed	26/01/2016	0	08/01/2016	Recruitment Finished	Strict eligibility criteria, difficult to meet criteria with this patient group.
14/LO/1490	CHECKMATE 172: A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal	Number Agreed	6	Date Agreed	30/04/2019	13	25/01/2016	Recruitment Finished	Target Achieved
14/LO/1798	NCRN - 3312 - MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer: A Phase III open-label multicenter randomised study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) compared to chemotherapy in patients with locally adva	Number Agreed	6	Date Agreed	18/12/2017	13	29/01/2016	Recruitment Finished	Target Achieved
14/SW/0091	NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC: NSCLC M11089 A Phase 3 Veliparib plus Chemotherapy Study in Adv/Met squamous NSCLC	Number Agreed	4	Date Agreed	31/03/2016	8	12/02/2016	Recruitment Finished	Target Achieved
14/SW/1164	HAWK - CANC3672 - D4193C00001	Number Agreed	3	Date Agreed	01/02/2017	1	31/03/2016	Recruitment Finished	Rare patient group. 8 patients pre-screened/approached and 1 recruited. Non entry as follows: 6 consented but screen failed on central pathology review, 1 patient declined.
15/NE/0149	CANC - 3928 - CONDOR	Number Agreed	2	Date Agreed	31/01/2017	3	31/03/2016	Recruitment Finished	Target Achieved
15/SC/0676	ANNOUNCE - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma	Number Agreed	2	Date Agreed	30/08/2019	2	27/05/2016	Recruitment Finished	Target Achieved

13/WM/0421	TARGOVAX: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas	Number Agreed	10	Date Agreed	01/04/2016	12	02/05/2016	Recruitment Finished	Target Achieved
15/EM/0305	CANC - 4278 - GTx-024 in Advanced, AR+ TNBC: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)	Number Agreed	2	Date Agreed	02/09/2016	0	12/09/2016	Withdrawn By Sponsor	Unable to achieve recruitment target as Sponsor withdrew the study in the UK due to lack of recruitment.
15/EE/0385	NEPTUNE Lung: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non	Number Agreed	4	Date Agreed	24/09/2018	5	07/09/2016	Withdrawn By Host	Target Achieved
14/LO/0135	BAYER 15396: A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na?ve subject	Number Agreed	6	Date Agreed	30/07/2021	5	22/08/2016	Recruitment Finished	Study closed as recruitment target achieved nationally.
15/LO/0448	RAINFALL: NCRN3464 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	12	Date Agreed	31/12/2018	8	18/08/2016	Recruitment Finished	Study closed earlier than planned as recruitment target achieved nationally.
15/EE/0013	A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with o	Number Agreed	4	Date Agreed	27/05/2016	8	13/07/2016	Recruitment Finished	Target Achieved
13/LO/1277	SPARTAN - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer	Number Agreed	6	Date Agreed	08/11/2018	10	21/06/2016	Recruitment Finished	Target Achieved
15/LO/0691	Checkmate - 171: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen fo	Number Agreed	4	Date Agreed	30/05/2016	23	31/05/2016	Recruitment Finished	Target Achieved